Taiwan's Biotech Sector Plan Stalled By Funding Limitations, Wary Investors
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Taiwan's aspirations to become a regional biotech powerhouse have been delayed in the last year by overly stringent requirements and a lack of professionals to undertake two key portions of a four-part industry development blueprint